Amicus Therapeutics(US:FOLD)2025-11-04 13:30Financial Performance - Q3 2025 total revenue reached $169 million, a 17% increase[4,59] - Galafold revenue in Q3 2025 was $138.3 million[9,13] - Pombiliti + Opfolda revenue in Q3 2025 was $30.7 million, representing a 42% increase[26] - The company anticipates surpassing $1 billion in total revenue in FY 2028[5] - Non-GAAP net income for Q3 2025 was $54.2 million[59] Galafold Performance - Galafold revenue grew 15% in Q3 2025[11] - Approximately 2,730 individuals are currently being treated with Galafold[9] - Galafold holds a 69% share of treated amenable patients[9] Pombiliti + Opfolda Performance - Pombiliti + Opfolda revenue is expected to grow 50-65% in FY 2025[4,28] - The number of naïve starts for Pombiliti + Opfolda doubled in the first 9 months of 2025 compared to FY 2024[31]